Cabozantinib After Immunotherapy in Advanced Renal Cell Carcinoma. The CARE Study by the Hellenic Gu Cancer Group. (PubMed, Cancer Manag Res) - Sep 23, 2026 - "Prior immunotherapy consisted mainly of nivolumab monotherapy or nivolumab plus ipilimumab, while cabozantinib was administered predominantly as second-line treatment...In this real-world Greek cohort, cabozantinib demonstrated meaningful clinical activity and an acceptable safety profile in mRCC patients progressing after ICI-based therapy. These findings support cabozantinib as an effective treatment option in the post-immunotherapy setting and contribute valuable real-world evidence to inform therapeutic sequencing in mRCC."
Journal • Fatigue • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Areti Mamali; Aristotelis Bamias; Christos Christodoulou; Dimitra Stefanou; Dimitrios C Ziogas; Dimitrios Deligiannis; Efstathia Giannopoulou; Ioanna Katsiana; Ioannis Binas; Kimon Tzannis; Konstantina Kakogianni; Meletios Athanasios Dimopoulos; Meropi Galari; Michael Chrisofos; Michael Liontos; Napoleon Moulavasilis; Nikolaos Dedes; Roubini Zakopoulou; Vasiliki Magoula; Vasiliki Nikolaidou
|